These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 8009486

  • 1. [Antihypertensive treatment and risk of coronary disease. How significant is the antihypertensive effect for metabolic factors?].
    Moan A, Os I, Hjermann I, Kjeldsen SE.
    Tidsskr Nor Laegeforen; 1994 Feb 10; 114(4):462-4. PubMed ID: 8009486
    [Abstract] [Full Text] [Related]

  • 2. [Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)].
    Klein W.
    Z Kardiol; 1992 Jun 10; 81(6):295-302. PubMed ID: 1353932
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety of antihypertensive therapy.
    Grossman E, Messerli FH.
    Prog Cardiovasc Dis; 2006 Jun 10; 49(1):16-25. PubMed ID: 16867847
    [Abstract] [Full Text] [Related]

  • 4. [Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension].
    Sawicki PT.
    Wien Klin Wochenschr; 1995 Jun 10; 107(21):629-39. PubMed ID: 8578749
    [Abstract] [Full Text] [Related]

  • 5. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C, Canadian Hypertension Education Program.
    Can J Cardiol; 2004 Jan 10; 20(1):41-54. PubMed ID: 14968142
    [Abstract] [Full Text] [Related]

  • 6. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B, Brilla C, Kruse T, Noll B, Bethge C.
    Herz; 1995 Dec 10; 20(6):370-89. PubMed ID: 8582697
    [Abstract] [Full Text] [Related]

  • 7. Hypertension therapy and risk of coronary heart disease: how do antihypertensives affect metabolic factors?
    Moan A, Os I, Hjermann I, Kjeldsen SE.
    Cardiology; 1995 Dec 10; 86(2):89-93. PubMed ID: 7728812
    [Abstract] [Full Text] [Related]

  • 8. [Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension].
    Román O, Cuevas G, Bunout D.
    Rev Med Chil; 1998 Jul 10; 126(7):745-52. PubMed ID: 9830766
    [Abstract] [Full Text] [Related]

  • 9. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M.
    Am J Ther; 2007 Jul 10; 14(4):386-402. PubMed ID: 17667215
    [Abstract] [Full Text] [Related]

  • 10. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, ALLHAT Collaborative Research Group.
    Arch Intern Med; 2006 Nov 13; 166(20):2191-201. PubMed ID: 17101936
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive drug therapy and coronary heart disease risk.
    Schoenberger JA.
    J Fam Pract; 1993 Jan 13; 36(1):70-3, 77-84. PubMed ID: 8419507
    [Abstract] [Full Text] [Related]

  • 12. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG, Yao XY, Tao QM, Zheng P, Chen JZ, Zhu JH, Zhang FR, Zheng LR, Zhao LL.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug 13; 25(8):710-4. PubMed ID: 15555399
    [Abstract] [Full Text] [Related]

  • 13. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S, Bakir SE.
    Drugs; 2000 Aug 13; 59 Spec No 2():25-37. PubMed ID: 11002856
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar 13; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 15. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD, Canadian Hypertension Education Program.
    Can J Cardiol; 2005 Jun 13; 21(8):657-72. PubMed ID: 16003449
    [Abstract] [Full Text] [Related]

  • 16. [Are all antihypertensive drugs renoprotective?].
    Wolf S, Risler T.
    Herz; 2004 May 13; 29(3):248-54. PubMed ID: 15167950
    [Abstract] [Full Text] [Related]

  • 17. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 18. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr 25; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T, Linjer E, Hedner T, Lanke J, De Faire U, Wester PO, Dahlöf B, Scherstén B.
    Blood Press; 2004 Apr 25; 13(3):137-41. PubMed ID: 15223721
    [Abstract] [Full Text] [Related]

  • 20. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G, Scientific Council of the European Society of Hypertension.
    J Hypertens; 2008 Oct 25; 26(10):1891-900. PubMed ID: 18806611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.